---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-004279"
form_type: "8-K"
ticker: "SER"
cik: "0001708599"
company_name: "Serina Therapeutics, Inc."
filed_at: "2023-02-10T23:59:59+00:00"
generated_at: "2026-06-19T18:07:12.834356+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# AgeX Therapeutics amends convertible note with Juvenescence, adds $2M incremental borrowing capacity

## Summary
- AgeX may borrow up to an additional $2M from Juvenescence until May 9, 2023, subject to lender's discretion.
- Maximum single draw is $1M; total existing loan principal outstanding is $13.16M.
- Repayment date remains February 14, 2024; warrants equal to 50% of each advance granted to Juvenescence.
- Amended Note also reaffirms security interests and prior agreements including Warrant Agreement.

## SEC filing metadata
- accession: 0001493152-23-004279
- form_type: 8-K
- ticker: SER
- cik: 0001708599
- company_name: Serina Therapeutics, Inc.
- filed_at: 2023-02-10T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708599/000149315223004279/0001493152-23-004279-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708599/000149315223004279/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-004279
- JSON: https://secwatch.observer/filing/0001493152-23-004279.json
- Plain text: https://secwatch.observer/filing/0001493152-23-004279.txt

## Key facts
- Material Agreements
  Serina Therapeutics, Inc. entered into Reaffirmation and Amendment Agreement with Juvenescence Limited (effective 2023-02-09).
  - Action: entry
  - Counterparty: Juvenescence Limited
  - Effective: 2023-02-09
  source text: In connection with the Amended Note, AgeX and Juvenescence entered into a Reaffirmation and Amendment Agreement (the "Reaffirmation Agreement") pursuant to which AgeX reaffirmed its obligations under certain agreements between AgeX and Juvenescence that originally pertained to the Original Note, including but not limited to (i) the Security Agreement, (ii) a Registration Rights Agreement, as amended, and (iii) a Warrant Agreement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708599/000149315223004279/0001493152-23-004279-index.htm
- Material Agreements
  Serina Therapeutics, Inc. entered into Amended and Restated Secured Convertible Promissory Note with Juvenescence Limited valued at additional $2,000,000 (effective 2023-02-09).
  - Action: entry
  - Agreement: notes offering
  - Counterparty: Juvenescence Limited
  - Value: additional $2,000,000
  - Effective: 2023-02-09
  source text: On February 9, 2023, AgeX and Juvenescence Limited ("Juvenescence") entered into an Amended and Restated Secured Convertible Promissory Note (the "Amended Note") which amends and restates a February 14, 2022 Secured Convertible Promissory Note (the "Original Note") and provides that AgeX may borrow up to an additional $2,000,000 from Juvenescence until May 9, 2023 subject to Juvenescence’s discretion to approve each loan draw.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708599/000149315223004279/0001493152-23-004279-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.